You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Research & Development
Veralox Therapeutics Submits IND to US FDA for Phase I Trial of VLX-1005 to Treat Heparin-Inducted Thrombocytopenia
Login
Username:

Password:


Related Headlines

AbbVie receives positive CHMP opinion for upadacitinib in severe alopecia areata

AbbVie receives positive CHMP opinion for upadacitinib in non‑segmental vitiligo

genedrive partners with Thermo Fisher Scientific to develop high-throughput CYP2C19 test

Sobi receives US FDA's complete response letter for NASP (nanoencapsulated sirolimus plus pegadricase)

Anivive Lifesciences' Laverdia receives FDA approval to treat canine lymphoma

Lupin's Enzalutamide Tablets receive for tentative US FDA approval

Vifor Fresenius and CSL announce European regulator recommends revoking TAVNEOS (avacopan) marketing authorisation

bioMérieux files FDA application for rapid vaginitis diagnostic panel

FDA approves Merck's Keytruda combinations for first-line treatment of PD-L1-positive advanced triple-negative breast cancer

Ionis licenses ex-US rights to zilganersen for Alexander disease to Recordati

Dicot Pharma receives FDA clearance to start Phase 2b study of LIB-01 in US

CeleCor Therapeutics submits final section of zalunfiban (Disaggpro) New Drug Application to US FDA

Thalia Therapeutics acquires Sanmirna and raises GBP2.75m to advance AML RNA therapy

ZETA SURGICAL reports first patient treated with Zeta TMS Navigation System at HOPE Therapeutics

EU approves MAVIRET for acute hepatitis C treatment

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026